228 related articles for article (PubMed ID: 8091766)
21. Posttraumatic parathyroid crisis and severe hypercalcemia treated with intravenous bisphosphonate (APD). Case report.
Canivet JL; Damas P; Lamy M
Acta Anaesthesiol Belg; 1990; 41(1):47-50. PubMed ID: 2360392
[TBL] [Abstract][Full Text] [Related]
22. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.
Wimalawansa SJ
Cancer; 1994 Apr; 73(8):2223-30. PubMed ID: 8156530
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134
[TBL] [Abstract][Full Text] [Related]
24. Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy.
Fraser WD; Logue FC; Gallacher SJ; O'Reilly DS; Beastall GH; Ralston SH; Boyle IT
Bone Miner; 1991 Feb; 12(2):113-21. PubMed ID: 1849762
[TBL] [Abstract][Full Text] [Related]
25. Aminopropylidine diphosphonate (APD) in mild primary hyperparathyroidism: effect on clinical status.
Schmidli RS; Wilson I; Espiner EA; Richards AM; Donald RA
Clin Endocrinol (Oxf); 1990 Mar; 32(3):293-300. PubMed ID: 2188763
[TBL] [Abstract][Full Text] [Related]
26. Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate.
Thiébaud D; Jacquet AF; Burckhardt P
Arch Intern Med; 1990 Oct; 150(10):2125-8. PubMed ID: 2222097
[TBL] [Abstract][Full Text] [Related]
27. Thiazide Treatment in Primary Hyperparathyroidism-A New Indication for an Old Medication?
Tsvetov G; Hirsch D; Shimon I; Benbassat C; Masri-Iraqi H; Gorshtein A; Herzberg D; Shochat T; Shraga-Slutzky I; Diker-Cohen T
J Clin Endocrinol Metab; 2017 Apr; 102(4):1270-1276. PubMed ID: 28388724
[TBL] [Abstract][Full Text] [Related]
28. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
29. Treatment of malignancy-associated hypercalcemia with YM175, a new bisphosphonate: elevated threshold for parathyroid hormone secretion in hypercalcemic patients.
Fukumoto S; Matsumoto T; Takebe K; Onaya T; Eto S; Nawata H; Ogata E
J Clin Endocrinol Metab; 1994 Jul; 79(1):165-70. PubMed ID: 8027221
[TBL] [Abstract][Full Text] [Related]
30. Persistent elevated serum levels of intact parathyroid hormone after reoperation for primary hyperparathyroidism and after pamidronate therapy.
Darcan S; Coker M; Aydinok Y; Gökşen D; Ozok G
Turk J Pediatr; 2003; 45(3):269-72. PubMed ID: 14696811
[TBL] [Abstract][Full Text] [Related]
31. Daily follow-up of serum parathyroid hormone and calcium after surgery for primary hyperparathyroidism.
Debruyne F; Delaere P; Ostyn F; Van den Bruel A; Bouillon R
J Otolaryngol; 1999 Dec; 28(6):305-8. PubMed ID: 10604157
[TBL] [Abstract][Full Text] [Related]
32. Uses and effectiveness of pamidronate disodium for treatment of dogs and cats with hypercalcemia.
Hostutler RA; Chew DJ; Jaeger JQ; Klein S; Henderson D; DiBartola SP
J Vet Intern Med; 2005; 19(1):29-33. PubMed ID: 15715044
[TBL] [Abstract][Full Text] [Related]
33. Hypercalcemia: A Review.
Walker MD; Shane E
JAMA; 2022 Oct; 328(16):1624-1636. PubMed ID: 36282253
[TBL] [Abstract][Full Text] [Related]
34. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.
Gucalp R; Ritch P; Wiernik PH; Sarma PR; Keller A; Richman SP; Tauer K; Neidhart J; Mallette LE; Siegel R
J Clin Oncol; 1992 Jan; 10(1):134-42. PubMed ID: 1727915
[TBL] [Abstract][Full Text] [Related]
35. Hypercalcemia associated with tertiary hyperparathyroidism managed conservatively with pamidronate in a hemodialysis patient.
Czosnowski LM; Hudson JQ; Canada RB
Am J Med Sci; 2009 Apr; 337(4):300-1. PubMed ID: 19365180
[TBL] [Abstract][Full Text] [Related]
36. [Pamidronate in the treatment of tumor-associated hypercalcemia].
Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H
Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492
[TBL] [Abstract][Full Text] [Related]
37. A comparison of single and multiple intravenous infusions of 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (APD) in the treatment of hypercalcemia of malignancy.
Yates AJ; Murray RM; Jerums GJ; Martin TJ
Aust N Z J Med; 1987 Aug; 17(4):387-91. PubMed ID: 3435316
[TBL] [Abstract][Full Text] [Related]
38. Primary hyperparathyroidism and severe hypercalcemia with low circulating 1,25-dihydroxyvitamin D.
Shaker JL; Krawczyk KW; Findling JW
J Clin Endocrinol Metab; 1990 Nov; 71(5):1305-9. PubMed ID: 2229288
[TBL] [Abstract][Full Text] [Related]
39. Disodium pamidronate versus mithramycin in the management of tumour-associated hypercalcemia.
Ostenstad B; Andersen OK
Acta Oncol; 1992; 31(8):861-4. PubMed ID: 1290634
[TBL] [Abstract][Full Text] [Related]
40. Increased prevalence of primary hyperparathyroidism in treated breast cancer.
Fierabracci P; Pinchera A; Miccoli P; Conte PF; Vignali E; Zaccagnini M; Marcocci C; Giani C
J Endocrinol Invest; 2001 May; 24(5):315-20. PubMed ID: 11407650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
